Indiviors former parent ponies up a whopping $1.4B to settle Suboxone marketing probe

fiercepharma | July 11, 2019

Indiviors former parent ponies up a whopping $1.4B to settle Suboxone marketing probe
With the feds sniffing around Indiviors aggressive marketing of its opioid addiction treatment Suboxone, the forecast looked bleak for the drugmaker. The stink was bad enough that Indivior’s former parent company is paying a steep price to clear its name—to the tune of $1.4 billion. Reckitt Benckiser settled with the Justice Department and Federal Trade Commission for $1.4 billion Thursday to end multiple federal probes into an alleged scheme to push sales of the opioid addiction treatment Suboxone Film. The payout ranks as one of the largest in recent memory for pharma marketing, with only a handful of drugmakers ever having paid billion-dollar settlements. The single largest settlement on record was GlaxoSmithKline's criminal and civil payout of $3 billion in 2012, with the most recent seven-figure check signed by Teva in 2015 for $1.2 billion. Reckitt's settlement only covers allegations dating to the period before Indivior's 2014 spinoff, Indivior said in a statement. Reckitt was not directly named in the feds' criminal investigation, and prosecutors are still investigating Indivior’s own marketing of Suboxone. The company was indicted on criminal charges in April. “While RB has acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct, after careful consideration, the Board of RB determined that the agreement is in the best interests of the company and its shareholders,” the company said in a statement. While the settlement could represent a “high-water mark” for a possible payout from Indivior, the Suboxone maker will likely fight its case in court, which could take years, Jefferies analysts said in a note to investors Thursday.

Spotlight

Drug and Medicine are two similar words and can be used as synonyms for each other. Most of persons get confused while differentiating between these.

Related News

PHARMACY MARKET

Rx-360 Launches New auditsPlus®

Rx-360 | June 10, 2021

Rx-360, a global pharmaceutical consortium committed to supply chain integrity and patient safety, is happy to announce the extension of our Audit Program. The release of the new Rx-360 auditsPlus database is the key driver of this growth. This interactive, user-friendly database will not only raise awareness of the Rx-360 Joint Audit Program®. Still, it will also provide Rx-360 program users with new and improved tools to minimize their audit burden. Rx-360's CEO, Jim Fries, stated, "Maintaining quality in pharmaceutical materials is an ever-increasing problem for the pharmaceutical sector. To maintain our commitment to patient safety, this new tool will provide users of our software with better insight into Rx-360 audits. It's another benefit we can provide the industry and our members." Jaye Greene, Rx-360's Head of Audit Operations and Quality, stated, "We are extremely excited to introduce the market to our new auditsPlus platform. The user experience has been greatly improved, and all of the Rx-360 Audit Programs are now easily accessible." About Rx-360 Rx-360, an international pharmaceutical supply chain consortium, was founded in 2009 to support an industry-wide commitment to maintaining patient safety via improved quality and authenticity across the supply chain. The organization's objective is to ensure patient safety by exchanging information and developing processes related to the integrity of the healthcare supply chain and the quality of products used in the supply chain. Rx-360 contains work streams relating to audit and sharing review reports, supply chain security, monitoring and reporting, Asia-focused activities, supplier-focused initiatives, and external relations, communications, and membership to fulfill this mission.

Read More

Allied Expands Pharmaceutical Pipeline By Filing US Provisional Patent for Psilocybin Based Therapeutics

Allied Corp | October 21, 2020

Allied Corp, an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the filing of a new United States provisional patent application entitled “PSILOCYBIN COMPOSITIONS AND FORMULATIONS AND THEIR USE IN TREATING MENTAL HEALTH DISORDERS AND IMPROVING MENTAL HEALTH”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom formulation, as well as a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression and General Anxiety. Psilocybin is the active pharmaceutical ingredient contained in the Golden Teacher psychedelic mushroom. Along with the novel treatment regimen, Allied’s formulation consists of novel micro-dose ratios of several medical mushroom compounds combined with additional natural health molecules.

Read More

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19

Novartis | June 26, 2020

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today. The research – which covered 2,502 tech professionals in the USA, UK, Germany, China and India, conducted between May and June 2020 – targeted respondents from a variety of sectors and organizations with the objective to study perception shifts of the industry in the wake of the global COVID-19 pandemic. For Novartis, a leading global medicines company, investing in and progressing data and digital capabilities is central to its work to reimagine medicine. As the company continues to grow its team of world-leading tech talent, through partnerships and hires, the research explored whether those in tech are aware of role they could play in helping to solve the world’s biggest medicine challenges now and in the future.

Read More

Spotlight

Drug and Medicine are two similar words and can be used as synonyms for each other. Most of persons get confused while differentiating between these.